INS and type 2 diabetes mellitus: In controlled trials ranging in treatment duration from 12 to 52 weeks where HbA1c reduction was a primary endpoint, ExBID as monotherapy and in various combinations with MET, SFU, TZD, and insulins reduced mean HbA1c by -0.8% to -1.7% in T2DM patients with mean baseline HbA1c values ranging from 7.5% to 10.2% (Tables 1 and 2) [86-120].1,2 The percentage of patients with T2DM achieving HbA1c values ≤7% with ExBID ranged from 20% to 79%, depending upon the baseline characteristics of the patient populations, their concomitant medications, and the active treatment regimen.